Kabi Awaits Biosimilar Tocilizumab Boost, Upgrades 2024 Guidance
Follows Recent US Launch And Increasing European Roll Out, ‘Very Confident’
Fresenius Kabi enjoyed a good start to 2024, boosted by the recent US launch of its biosimilar tocilizumab product and a key licensing agreement signed with Teva – factors that have allowed the German generics and biosimilars giant to boost its financial guidance for 2024.
